# ADMA BIOLOGICS, INC. stock analysis

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indica

## Market evidence and data freshness

The public preview recorded ADMA BIOLOGICS, INC. at 10.12 USD on 2026-09-28T20:00:01.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2021-09-30 through 2026-09-25 across 1251 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## What should I review before buying ADMA BIOLOGICS, INC. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/adma)